The FIGO systems for nomenclature and classification of causes of abnormal uterine bleeding in the reproductive years: who needs them?
In November 2010, the International Federation of Gynecology and Obstetrics formally accepted a new classification system for causes of abnormal uterine bleeding in the reproductive years. The system, based on the acronym PALM-COEIN (polyps, adenomyosis, leiomyoma, malignancy and hyperplasia–coagulopathy, ovulatory disorders, endometrial causes, iatrogenic, not classified) was developed in response to concerns about the design and interpretation of basic science and clinical investigation that relates to the problem of abnormal uterine bleeding. A system of nomenclature for the description of normal uterine bleeding and the various symptoms that comprise abnormal bleeding has also been included. This article describes the rationale, the structured methods that involved stakeholders worldwide, and the suggested use of the International Federation of Gynecology and Obstetrics system for research, education, and clinical care. Investigators in the field are encouraged to use the system in the design of their abnormal uterine bleeding–related research because it is an approach that should improve our understanding and management of this often perplexing clinical condition.
Key words: abnormal uterine bleeding , classification system , FIGO , heavy menstrual bleeding , leiomyoma
To access this article, please choose from the options below
Funded by an unrestricted educational grant to the Association of Academic Health Centers from TAP Pharmaceuticals, Chicago, IL, and Schering AG, Berlin, Germany; subsequent funding was provided by an unrestricted grant to the Royal Australian and New Zealand College of Obstetricians and Gynaecologists by Bayer Women's Health, Berlin, Germany.
All authors act as consultants to Bayer Health Care; H.O.D.C. has received support for research collaboration from Bayer Pharma AG and also past support (research grant) from TAP Pharmaceutical Products Inc; I.S.F. has received research grants from Bayer Health Care.
PII: S0002-9378(12)00140-8
doi:10.1016/j.ajog.2012.01.046
© 2012 Published by Elsevier Inc.
